Neil Cashman

Company: ProMIS Neurosciences

Job title: Chief Scientific Officer & Co-Founder

Seminars:

PM310: the Next Generation of Anti-Amyloid Antibodies that Avoid ARIA to Improve Safety 12:00 pm

Oligomer specificity can be generated Specificity for oligomers will reduce competition by Amyloid beta monomers Specificity for oligomers will improve safety by reducing ARIARead more

day: Clinical & Commercial Track AM

Panel Discussion: Is Plaque Reduction a Valid Marker of Response & Sufficiently Relevant to Drug Efficacy? 9:00 am

Navigating how the recent approval of amyloid clearing antibody drugs will affect regulator perception of plaque reduction as a marker of drug efficacy Reviewing if plaque targeting is relevant for drugs with a different mechanism of action and if this affects the safety profile too significantly Exploring the relevance of plaque clearance in heterogenous pathology…Read more

day: Conference Day One